{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:54:13Z","timestamp":1791579253044,"version":"4.3.4"},"reference-count":313,"publisher":"Endocrinology Research Centre","issue":"4","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Primary hyperparathyroidism (PHPT) is an endocrine disorder of parathyroid glands characterized by excessive secretion of parathyroid hormone (PTH) with an upper normal or elevated blood calcium level. Classical PHPT refers to a symptomatic, multi-system disorder, wich can lead to a significant decrease in the quality of life, disability of patients, and even an increased risk of premature death. Hypercalcemia and the catabolic effect of PTH on various cells are considered as the main pathogenetic mechanisms of the PHPT associated complications. In the last two decades, there has been an increase in the incidence of PHPT, mainly due to the mild forms of the disease, primarily due to the routine calcium screening in North America, Western Europe and, Asia. High prevalence of the disease, as well as the variety of clinical manifestations, cause the attention of different specialists - physicians, rheumatologists, urologists, nephrologists, cardiologists and other doctors. This review cover the main issues of Russian guidelines for the management of PHPT, approved in 2020, including laboratory and instrumental methods, differential diagnosis, surgical and conservative approach, short-term and long-term follow-up. This guidelines also include the recommendations for special groups of patients with hereditary forms of PHPT, parathyroid carcinoma, PHPT during pregnancy.<\/jats:p>","DOI":"10.14341\/probl12801","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T05:38:19Z","timestamp":1631857099000},"page":"94-124","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":58,"title":["The clinical practice guidelines for primary hyperparathyroidism, short version"],"prefix":"10.14341","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-9742","authenticated-orcid":true,"given":"N. G.","family":"Mokrysheva","sequence":"first","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-062X","authenticated-orcid":true,"given":"A. K.","family":"Eremkina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-0397","authenticated-orcid":true,"given":"S. S.","family":"Mirnaya","sequence":"additional","affiliation":[{"name":"Family Medical Centers Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-5022","authenticated-orcid":true,"given":"J. A.","family":"Krupinova","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-3240","authenticated-orcid":true,"given":"I. A.","family":"Voronkova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-259X","authenticated-orcid":true,"given":"I. V.","family":"Kim","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-4584","authenticated-orcid":true,"given":"D. G.","family":"Beltsevich","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-7013","authenticated-orcid":true,"given":"N. S.","family":"Kuznetzov","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-466X","authenticated-orcid":true,"given":"E. A.","family":"Pigarova","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-0732","authenticated-orcid":true,"given":"L. Ya.","family":"Rozhinskaya","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-2607","authenticated-orcid":true,"given":"M. V.","family":"Degtyarev","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-1901","authenticated-orcid":true,"given":"L. V.","family":"Egshatyan","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-634X","authenticated-orcid":true,"given":"P. A.","family":"Rumiantsev","sequence":"additional","affiliation":[{"name":"International Medical Center \u00abSOGAZ\u00bb"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-0020","authenticated-orcid":true,"given":"E. N.","family":"Andreeva","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-2997","authenticated-orcid":true,"given":"M. B.","family":"\u0410ntsiferov","sequence":"additional","affiliation":[{"name":"M.F. Vladimirsky Moscow Regional Research Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-1726","authenticated-orcid":true,"given":"N. V.","family":"Markina","sequence":"additional","affiliation":[{"name":"Moscow Health Care Department, Endocrinology Dispanserium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-5105","authenticated-orcid":true,"given":"I. V.","family":"Kryukova","sequence":"additional","affiliation":[{"name":"M.F. Vladimirsky Moscow Regional Research Clinical Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-0123","authenticated-orcid":true,"given":"T. L.","family":"Karonova","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre St. Petersburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3317-0108","authenticated-orcid":true,"given":"S. V.","family":"Lukyanov","sequence":"additional","affiliation":[{"name":"Rostov State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-5081","authenticated-orcid":true,"given":"I. V.","family":"Sleptcov","sequence":"additional","affiliation":[{"name":"Saint-Petersburg State University (SPSU) N.I. Pirogov Clinic of High Medical Technologies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-9291","authenticated-orcid":true,"given":"N. B.","family":"Chagai","sequence":"additional","affiliation":[{"name":"Stavropol State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":true,"given":"G. A.","family":"Melnichenko","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-7886","authenticated-orcid":true,"given":"I. I.","family":"Dedov","sequence":"additional","affiliation":[{"name":"Endocrinology Resarch Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mokrysheva NG, Rozhinskaia LI, Peretokina EV, et al. The results of analysis of the major epidemiological characteristics of primary hyperparathyroidism in Russia based on the registry data. Problems of Endocrinology. 2012;58(5):16-20. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl201258516-20","DOI":"10.14341\/probl201258516-20"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Prim. 2016;2(1):16033. doi: https:\/\/doi.org\/10.1038\/nrdp.2016.33","DOI":"10.1038\/nrdp.2016.33"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi: https:\/\/doi.org\/10.1007\/s12020-016-1169-1","DOI":"10.1007\/s12020-016-1169-1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Cromer MK, Starker LF, Choi M, et al. Identification of Somatic Mutations in Parathyroid Tumors Using Whole-Exome Sequencing. J Clin Endocrinol Metab. 2012;97(9):E1774-E1781. doi: https:\/\/doi.org\/10.1210\/jc.2012-1743","DOI":"10.1210\/jc.2012-1743"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Thakker RV. Genetics of parathyroid tumours. J Intern Med. 2016;280(6):574-583. doi: https:\/\/doi.org\/10.1111\/joim.12523","DOI":"10.1111\/joim.12523"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Bricaire L, Odou M-F, Cardot-Bauters C, et al. Frequent Large Germline HRPT2 Deletions in a French National Cohort of Patients With Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(2):E403-E408. doi: https:\/\/doi.org\/10.1210\/jc.2012-2789","DOI":"10.1210\/jc.2012-2789"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Warner J. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004;41(3):155-160. doi: https:\/\/doi.org\/10.1136\/jmg.2003.016725","DOI":"10.1136\/jmg.2003.016725"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1-19. doi: https:\/\/doi.org\/10.1007\/s00198-016-3716-2","DOI":"10.1007\/s00198-016-3716-2"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Clarke BL, Asymptomatic Primary Hyperparathyroidism, in Parathyroid Disorders. 2019, Karger Publishers. P. 13-22.","DOI":"10.1159\/000491035"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. J Clin Endocrinol Metab. 2013;98(7):2734-2741. doi: https:\/\/doi.org\/10.1210\/jc.2013-1300","DOI":"10.1210\/jc.2013-1300"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf ). 2008;69(5):713-720. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03259.x","DOI":"10.1111\/j.1365-2265.2008.03259.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Nordenstr\u00f6m E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem. 2011;44(10-11):849-852. doi: https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.04.002","DOI":"10.1016\/j.clinbiochem.2011.04.002"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Amin AL, Wang TS, Wade TJ, Yen TWF. Normal PTH Levels in Primary Hyperparathyroidism: Still the Same Disease? Ann Surg Oncol. 2011;18(12):3437-3442. doi: https:\/\/doi.org\/10.1245\/s10434-011-1744-x","DOI":"10.1245\/s10434-011-1744-x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Monchik JM, Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136(6):1242-1246. doi: https:\/\/doi.org\/10.1016\/j.surg.2004.06.052","DOI":"10.1016\/j.surg.2004.06.052"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic Primary Hyperparathyroidism: Further Characterization of a New Clinical Phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-3005. doi: https:\/\/doi.org\/10.1210\/jc.2006-2802","DOI":"10.1210\/jc.2006-2802"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Silverberg SJ, Bilezikian JP. \u201cIncipient\u201d Primary Hyperparathyroidism: A \u201cForme Fruste\u201d of an Old Disease. J Clin Endocrinol Metab. 2003;88(11):5348-5352. doi: https:\/\/doi.org\/10.1210\/jc.2003-031014","DOI":"10.1210\/jc.2003-031014"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Maeda SS, Saraiva GL, Kunii IS, et al. Factors affecting vitamin D status in different populations in the city of S\u00e3o Paulo, Brazil: the S\u00e3o PAulo vitamin D Evaluation Study (SPADES). BMC Endocr Disord. 2013;13(1):14. doi: https:\/\/doi.org\/10.1186\/1472-6823-13-14","DOI":"10.1186\/1472-6823-13-14"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi: https:\/\/doi.org\/10.1210\/jc.2010-2704","DOI":"10.1016\/j.jada.2011.01.004"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29(4):496-502. doi: https:\/\/doi.org\/10.1016\/S0272-6386(97)90330-9","DOI":"10.1016\/S0272-6386(97)90330-9"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Walker MD, Dempster DW, McMahon DJ, et al. Effect of Renal Function on Skeletal Health in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2012;97(5):1501-1507. doi: https:\/\/doi.org\/10.1210\/jc.2011-3072","DOI":"10.1210\/jc.2011-3072"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973. doi: https:\/\/doi.org\/10.1172\/JCI107156","DOI":"10.1172\/JCI107156"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31(10):845-850. doi: https:\/\/doi.org\/10.1007\/BF03346429","DOI":"10.1007\/BF03346429"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Selby PL, Davies M, Adams JE, Mawer EB. Bone Loss in Celiac Disease Is Related to Secondary Hyperparathyroidism. J Bone Miner Res. 1999;14(4):652-657. doi: https:\/\/doi.org\/10.1359\/jbmr.1999.14.4.652","DOI":"10.1359\/jbmr.1999.14.4.652"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250(2):144-153. doi: https:\/\/doi.org\/10.1046\/j.1365-2796.2001.00868.x","DOI":"10.1046\/j.1365-2796.2001.00868.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Mallette LE, Khouri K, Zengotita H, et al. Lithium Treatment Increases Intact and Midregion Parathyroid Hormone and Parathyroid Volume*. J Clin Endocrinol Metab. 1989;68(3):654-660. doi: https:\/\/doi.org\/10.1210\/jcem-68-3-654","DOI":"10.1210\/jcem-68-3-654"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Makras P, Polyzos SA, Papatheodorou A, et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf ). 2013;79(4):499-503. doi: https:\/\/doi.org\/10.1111\/cen.12188","DOI":"10.1111\/cen.12188"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Fraser WD, Logue FC, Gallacher SJ, et al. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget\u2019s disease of bone and hypercalcaemia of malignancy. Bone Miner. 1991;12(2):113-121. doi: https:\/\/doi.org\/10.1016\/0169-6009(91)90040-7","DOI":"10.1016\/0169-6009(91)90040-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ud\u00e9n P, Chan A, Duh Q-Y, Siperstein A, Clark OH. Primary hyperparathyroidism in younger and older patients: Symptoms and outcome of surgery. World J Surg. 1992;16(4):791-797. doi: https:\/\/doi.org\/10.1007\/BF02067389","DOI":"10.1007\/BF02067389"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Reid LJ, Muthukrishnan B, Patel D, et al. Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centre\u2019s experience. Endocr Connect. 2018;7(10):1105-1115. doi: https:\/\/doi.org\/10.1530\/EC-18-0195","DOI":"10.1530\/EC-18-0195"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Monaco M Di, Vallero F, Monaco R Di, et al. Primary hyperparathyroidism in elderly patients with hip fracture. J Bone Miner Metab. 2004;22(5):491-495. doi: https:\/\/doi.org\/10.1007\/s00774-004-0512-4","DOI":"10.1007\/s00774-004-0512-4"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bergstr\u00f6m I, Landgren B-M, Freyschuss B. Primary hyperparathyroidism is common in postmenopausal women with forearm fracture and low bone mineral density. Acta Obstet Gynecol Scand. 2007;86(1):61-64. doi: https:\/\/doi.org\/10.1080\/00016340601033287","DOI":"10.1080\/00016340601033287"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Bandeira F, Griz L, Caldas G, et al. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metabol. 2006;50(4):657-663. doi: https:\/\/doi.org\/10.1590\/S0004-27302006000400011","DOI":"10.1590\/S0004-27302006000400011"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Khosla S, Melton LJ, Wermers RA, et al. Primary Hyperparathyroidism and the Risk of Fracture: A PopulationBased Study. J Bone Miner Res. 1999;14(10):1700-1707. doi: https:\/\/doi.org\/10.1359\/jbmr.1999.14.10.1700","DOI":"10.1359\/jbmr.1999.14.10.1700"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Yadav SK, Johri G, Bichoo RA, et al. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Arch Endocrinol Metab. 2020;64(2):4-6. doi: https:\/\/doi.org\/10.20945\/2359-3997000000211","DOI":"10.20945\/2359-3997000000211"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Wikstr\u00f6m B, Backman U, Danielson BG, et al. Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. Klin Wochenschr. 1983;61(2):85-90. doi: https:\/\/doi.org\/10.1007\/BF01496659","DOI":"10.1007\/BF01496659"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Fuss M, Pepersack T, Corvilain J, et al. Infrequency of Primary Hyperparathyroidism in Renal Stone Formers. Br J Urol. 1988;62(1):4-6. doi: https:\/\/doi.org\/10.1111\/j.1464-410X.1988.tb04254.x","DOI":"10.1111\/j.1464-410X.1988.tb04254.x"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Walker V, Stansbridge EM, Griffin DG. Demography and biochemistry of 2800 patients from a renal stones clinic. Ann Clin Biochem Int J Lab Med. 2013;50(2):127-139. doi: https:\/\/doi.org\/10.1258\/acb.2012.012122","DOI":"10.1258\/acb.2012.012122"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Sharma S, Rastogi A, Bhadada SK, et al. Prevalence and Predictors of Primary Hyperparathyroidism Among Patients with Urolithiasis. Endocr Pract. 2017;23(11):1311-1315. doi: https:\/\/doi.org\/10.4158\/EP171759.OR","DOI":"10.4158\/EP171759.OR"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kim J, Chai YJ, Chung JK, et al. The prevalence of primary hyperparathyroidism in Korea: a population-based analysis from patient medical records. Ann Surg Treat Res. 2018;94(5):235. doi: https:\/\/doi.org\/10.4174\/astr.2018.94.5.235","DOI":"10.4174\/astr.2018.94.5.235"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Sorensen MD, Duh Q-Y, Grogan RH, et al. Urinary Parameters as Predictors of Primary Hyperparathyroidism in Patients With Nephrolithiasis. J Urol. 2012;187(2):516-521. doi: https:\/\/doi.org\/10.1016\/j.juro.2011.10.027","DOI":"10.1016\/j.juro.2011.10.027"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Ebert EC. The Parathyroids and the Gut. J Clin Gastroenterol. 2010;44(7):479-482. doi: https:\/\/doi.org\/10.1097\/MCG.0b013e3181cd9d4c","DOI":"10.1097\/MCG.0b013e3181cd9d4c"},{"key":"ref42","unstructured":"Gasparoni P, Caroli A, Sardeo G, et al. Primary hyperparathyroidism and peptic ulcer. Minerva Med. 1989;80:1327-1330."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Jacob JJ, John M, Thomas N, et al. Does hyperparathyroidism cause pancreatitis? A South Indian experience and a review of published work. ANZ J Surg. 2006;76(8):740-744. doi: https:\/\/doi.org\/10.1111\/j.1445-2197.2006.03845.x","DOI":"10.1111\/j.1445-2197.2006.03845.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Inzucchi SE. Understanding hypercalcemia. Postgrad Med. 2004;115(4):69-76. doi: https:\/\/doi.org\/10.3810\/pgm.2004.04.1486","DOI":"10.3810\/pgm.2004.04.1486"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Walsh J, Gittoes N, Selby P, society for endocrinology endocrine emergency guidance: Emergency management of acute hypercalcaemia in adult patients. Endocr Connect. 2016;5(5):G9-G11. doi: https:\/\/doi.org\/10.1530\/EC-16-0055","DOI":"10.1530\/EC-16-0055"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Suh JM, Cronan JJ, Monchik JM. Primary Hyperparathyroidism: Is There an Increased Prevalence of Renal Stone Disease? Am J Roentgenol. 2008;191(3):908-911. doi: https:\/\/doi.org\/10.2214\/AJR.07.3160","DOI":"10.2214\/AJR.07.3160"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Cipriani C, Biamonte F, Costa AG, et al. Prevalence of Kidney Stones and Vertebral Fractures in Primary Hyperparathyroidism Using Imaging Technology. J Clin Endocrinol Metab. 2015;100(4):1309-1315. doi: https:\/\/doi.org\/10.1210\/jc.2014-3708","DOI":"10.1210\/jc.2014-3708"},{"key":"ref48","unstructured":"Miller PD, Bilezikian JP. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2002;17:98-102."},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Abboud B. Digestive manifestations of parathyroid disorders. World J Gastroenterol. 2011;17(36):4063. doi: https:\/\/doi.org\/10.3748\/wjg.v17.i36.4063","DOI":"10.3748\/wjg.v17.i36.4063"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med. 1989;87(5):553-557. doi: https:\/\/doi.org\/10.1016\/S0002-9343(89)80613-8","DOI":"10.1016\/S0002-9343(89)80613-8"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Coker LH, Rorie K, Cantley L, et al. Primary Hyperparathyroidism, Cognition, and HealthRelated Quality of Life. Ann Surg. 2005;242(5):642-650. doi: https:\/\/doi.org\/10.1097\/01.sla.0000186337.83407.ec","DOI":"10.1097\/01.sla.0000186337.83407.ec"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Morris GS, Grubbs EG, Hearon CM, et al. Parathyroidectomy Improves Functional Capacity in \u201cAsymptomatic\u201d Older Patients With Primary Hyperparathyroidism. Ann Surg. 2010;251(5):832-837. doi: https:\/\/doi.org\/10.1097\/SLA.0b013e3181d76bb3","DOI":"10.1097\/SLA.0b013e3181d76bb3"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569. doi: https:\/\/doi.org\/10.1210\/jc.2014-1413","DOI":"10.1210\/jc.2014-1413"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Ong GSY, Walsh JP, Stuckey BGA, et al. The Importance of Measuring Ionized Calcium in Characterizing Calcium Status and Diagnosing Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2012;97(9):3138-3145. doi: https:\/\/doi.org\/10.1210\/jc.2012-1429","DOI":"10.1210\/jc.2012-1429"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Thode J, Juul-J\u00f8rgensen B, Bhatia HM, et al. Comparison of serum total calcium, albumin-corrected total calcium, and ionized calcium in 1213 patients with suspected calcium disorders. Scand J Clin Lab Investig. 1989;49(3):217-223. doi: https:\/\/doi.org\/10.1080\/00365518909089086","DOI":"10.3109\/00365518909089086"},{"key":"ref56","unstructured":"Gao P, D\u2019Amour P. Evolution of the parathyroid hormone (PTH) assay- -importance of circulating PTH immunoheterogeneity and of its regulation. Clinical laboratory, 2005;51(1-2):21-29."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Boudou P, Ibrahim F, Cormier C, et al. Third- or Second-Generation Parathyroid Hormone Assays: A Remaining Debate in the Diagnosis of Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(12):6370-6372. doi: https:\/\/doi.org\/10.1210\/jc.2005-0715","DOI":"10.1210\/jc.2005-0715"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med. 2002;251(6):476-483. doi: https:\/\/doi.org\/10.1046\/j.1365-2796.2002.00984.x","DOI":"10.1046\/j.1365-2796.2002.00984.x"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Benson L, Ljunghall S, Groth T, et al. Optimal Discrimination of Mild Hyperparathyroidism with Total Serum Calcium, Ionized Calcium and Parathyroid Hormone Measurements. Ups J Med Sci. 1987;92(2):147-176. doi: https:\/\/doi.org\/10.3109\/03009738709178686","DOI":"10.3109\/03009738709178686"},{"key":"ref60","unstructured":"Forster J, Monchik JM, Martin HF. A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery. 1988;104(6):1137-1142. doi: https:\/\/doi.org\/10.5555\/uri:pii:0039606088901791"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Yamashita H, Noguchi S, Uchino S, et al. Influence of renal function on clinico-pathological features of primary hyperparathyroidism. Eur J Endocrinol. 2003;148(6):597-602. doi: https:\/\/doi.org\/10.1530\/eje.0.1480597","DOI":"10.1530\/eje.0.1480597"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Wang W-H, Chen L-W, Lee C-C, et al. Association between Parathyroid Hormone, 25 (OH) Vitamin D, and Chronic Kidney Disease: A Population-Based Study. Biomed Res Int. 2017;2017:1-9. doi: https:\/\/doi.org\/10.1155\/2017\/7435657","DOI":"10.1155\/2017\/7435657"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Tassone F, Gianotti L, Emmolo I, et al. Glomerular Filtration Rate and Parathyroid Hormone Secretion in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(11):4458-4461. doi: https:\/\/doi.org\/10.1210\/jc.2009-0587","DOI":"10.1210\/jc.2009-0587"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Muthukrishnan J, Kumar KVSH, Jha R, et al. Distal Renal Tubular Acidosis Due to Primary Hyperparathyroidism. Endocr Pract. 2008;14(9):1133-1136. doi: https:\/\/doi.org\/10.4158\/EP.14.9.1133","DOI":"10.4158\/EP.14.9.1133"},{"key":"ref65","unstructured":"Bilezikian JP, Meng X, Yifan S, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities \u2013 New York and Beijing. Int J Fertil Womens Med. 2000:45(2):158-165."},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Bandeira F, Caldas G, Freese E, et al. Relationship Between Serum Vitamin D Status and Clinical Manifestations of Primary Hyperparathyroidism. Endocr Pract. 2002;8(4):266-270. doi: https:\/\/doi.org\/10.4158\/EP.8.4.266","DOI":"10.4158\/EP.8.4.266"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf ). 2005;63(5):506-513. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02371.x","DOI":"10.1111\/j.1365-2265.2005.02371.x"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2010;54(2):106-109. doi: https:\/\/doi.org\/10.1590\/S0004-27302010000200004","DOI":"10.1590\/S0004-27302010000200004"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Eisner BH, Ahn J, Stoller ML. Differentiating Primary from Secondary Hyperparathyroidism in Stone Patients: The \u201cThiazide Challenge.\u201dJ Endourol. 2009;23(2):191-192. doi: https:\/\/doi.org\/10.1089\/end.2008.0567","DOI":"10.1089\/end.2008.0567"},{"key":"ref70","unstructured":"Pamputis SN, Lopatnicova EN. Differential diagnostics of normocalcemic hyperparathyrosys with use of diagnostic test with alfa-calcidol. Tavricheskii medikobiologicheskii vestnik. 2017;20(3-2):205-211. (In Russ.)"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of Age and Serum 25-OH-Vitamin D on Serum Parathyroid Hormone Levels. J Clin Endocrinol Metab. 2012;97(11):3989-3995. doi: https:\/\/doi.org\/10.1210\/jc.2012-2276","DOI":"10.1210\/jc.2012-2276"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkman M, Sorva A, Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: A systematic review of clinical trials. Arch Gerontol Geriatr. 2009;48(2):160-166. doi: https:\/\/doi.org\/10.1016\/j.archger.2007.12.005","DOI":"10.1016\/j.archger.2007.12.005"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Saliba W, Barnett O, Rennert HS, et al. The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels. Am J Med. 2011;124(12):1165-1170. doi: https:\/\/doi.org\/10.1016\/j.amjmed.2011.07.009","DOI":"10.1016\/j.amjmed.2011.07.009"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357(3):266-281. doi: https:\/\/doi.org\/10.1056\/NEJMra070553","DOI":"10.1056\/NEJMra070553"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Parfitt AM. The interactions of thiazide diuretics with parathyroid hormone and vitamin D. J Clin Invest. 1972;51(7):1879-1888. doi: https:\/\/doi.org\/10.1172\/JCI106990","DOI":"10.1172\/JCI106990"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Pigarova EA, Rozhinskaya LYa, Belaya ZhE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl201662460-84","DOI":"10.14341\/probl201662460-84"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Dedov II, Melnichenko GA, Mokrysheva NG, et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problems of Endocrinology. 2016;62(6):40-77. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl201662640-77","DOI":"10.14341\/probl201662640-77"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Cheung K, Wang TS, Farrokhyar F, et al. A Meta-analysis of Preoperative Localization Techniques for Patients with Primary Hyperparathyroidism. Ann Surg Oncol. 2012;19(2):577-583. doi: https:\/\/doi.org\/10.1245\/s10434-011-1870-5","DOI":"10.1245\/s10434-011-1870-5"},{"key":"ref79","unstructured":"Moghadam RN, Amlelshahbaz AP, Namiranian N, et al. Comparative diagnostic performance of ultrasonography and 99mTc-Sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; Systematic review and meta-analysis. Asian Pacific J Cancer Prev. 2017;18(12):3195. doi: https:\/\/doi.org\/10.22034\/APJCP.2017.18.12.3195"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Neck Surg. 2005;132(3):359-372. doi: https:\/\/doi.org\/10.1016\/j.otohns.2004.10.005","DOI":"10.1016\/j.otohns.2004.10.005"},{"key":"ref81","unstructured":"Artemova A. Sravnitel\u2019naya otsenka metodov topicheskoi diagnostiki pri pervichnom giperparatireoze. (Conference proceedigs). Tezisy dokladov Mezhdunarodnogo nauchnogo foruma \u00abPatologiya parashchitovidnykh zhelez: sovremennye podkhody k diagnostike i lecheniyu\u00bb; Sankt-Peterburg, 2010. P. 29-30. (In Russ.)"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Untch BR, Adam MA, Scheri RP, et al. Surgeon-Performed Ultrasound Is Superior to 99Tc-Sestamibi Scanning to Localize Parathyroid Adenomas in Patients with Primary Hyperparathyroidism: Results in 516 Patients over 10 Years. J Am Coll Surg. 2011;212(4):522-529. doi: https:\/\/doi.org\/10.1016\/j.jamcollsurg.2010.12.038","DOI":"10.1016\/j.jamcollsurg.2010.12.038"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Carlier T, Oudoux A, Miralli\u00e9 E, et al. 99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. Eur J Nucl Med Mol Imaging. 2008;35(3):637-643. doi: https:\/\/doi.org\/10.1007\/s00259-007-0625-9","DOI":"10.1007\/s00259-007-0625-9"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Witteveen JE, van Thiel S, Romijn JA, Hamdy NAT. Therapy of endocrine disease: Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45-R53. doi: https:\/\/doi.org\/10.1530\/EJE-12-0528","DOI":"10.1530\/EJE-12-0528"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Agha A, Hornung M, Schlitt HJ, et al. The role of contrast-enhancend ultrasonography (CEUS) in comparison with 99mTechnetiumsestamibi scintigraphy for localization diagnostic of primary hyperparathyroidism. Clin Hemorheol Microcirc. 2014;58(4):515-520. doi: https:\/\/doi.org\/10.3233\/CH-131800","DOI":"10.3233\/CH-131800"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Leslie W, Dupont J, Bybel B, Riese K. Parathyroid 99m Tc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout. Eur J Nucl Med Mol Imaging. 2002;29(12):1566-1570. doi: https:\/\/doi.org\/10.1007\/s00259-002-0944-9","DOI":"10.1007\/s00259-002-0944-9"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Wong KK, Fig LM, Gross MD, Dwamena BA. Parathyroid adenoma localization with 99mTc-sestamibi SPECT\/CT. Nucl Med Commun. 2015;36(4):363-375. doi: https:\/\/doi.org\/10.1097\/MNM.0000000000000262","DOI":"10.1097\/MNM.0000000000000262"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Lavely WC, Goetze S, Friedman KP, et al. Comparison of SPECT\/CT, SPECT, and Planar Imaging with Single- and Dual-Phase 99mTcSestamibi Parathyroid Scintigraphy. J Nucl Med. 2007;48(7):1084-1089. doi: https:\/\/doi.org\/10.2967\/jnumed.107.040428","DOI":"10.2967\/jnumed.107.040428"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Casara D., et al. Clinical role of 99m TcO 4\/MIBI scan, ultrasound and intra-operative gamma probe in the performance of unilateral and minimally invasive surgery in primary hyperparathyroidism. Eur J Nucl Med. 2001;28(9):1351-1359.","DOI":"10.1007\/s002590100564"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Kluijfhout WP, Pasternak JD, Beninato T, et al. Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. Eur J Radiol. 2017;88:117-128. doi: https:\/\/doi.org\/10.1016\/j.ejrad.2017.01.004","DOI":"10.1016\/j.ejrad.2017.01.004"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Kluijfhout WP, Pasternak JD, Drake FT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck\u2019s Arch Surg. 2016;401(7):925-935. doi: https:\/\/doi.org\/10.1007\/s00423-016-1425-0","DOI":"10.1007\/s00423-016-1425-0"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Wakamatsu H, Noguchi S, Yamashita H, et al. Parathyroid scintigraphy with 99mTc-MIBI and 123I subtraction: a comparison with magnetic resonance imaging and ultrasonography. Nucl Med Commun. 2003;24(7):755-762. doi: https:\/\/doi.org\/10.1097\/00006231-200307000-00004","DOI":"10.1097\/00006231-200307000-00004"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Ruf, J, et al. Preoperative localization of parathyroid glands. Nuklearmedizin, 2004;43(03):85-90. doi: https:\/\/doi.org\/10.1267\/NUKL04030085","DOI":"10.1055\/s-0038-1625596"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Noureldine SI, Aygun N, Walden MJ, et al. Multiphase computed tomography for localization of parathyroid disease in patients with primary hyperparathyroidism: How many phases do we really need? Surgery. 2014;156(6):1300-1307. doi: https:\/\/doi.org\/10.1016\/j.surg.2014.08.002","DOI":"10.1016\/j.surg.2014.08.002"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Takagi H, Tominaga Y, Uchida K, et al. Subtotal Versus Total Parathyroidectomy with Forearm Autograft for Secondary Hyperparathyroidism in Chronic Renal Failure. Ann Surg. 1984;200(1):18-23. doi: https:\/\/doi.org\/10.1097\/00000658-198407000-00003","DOI":"10.1097\/00000658-198407000-00003"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Harari A, Zarnegar R, Lee J, et al. Computed tomography can guide focused exploration in select patients with primary hyperparathyroidism and negative sestamibi scanning. Surgery. 2008;144(6):970-977. doi: https:\/\/doi.org\/10.1016\/j.surg.2008.08.029","DOI":"10.1016\/j.surg.2008.08.029"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Lubitz CC, Hunter GJ, Hamberg LM, et al. Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery. 2010;148(6):1129-1138. doi: https:\/\/doi.org\/10.1016\/j.surg.2010.09.002","DOI":"10.1016\/j.surg.2010.09.002"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Starker LF, Mahajan A, Bj\u00f6rklund P, et al. 4D Parathyroid CT as the Initial Localization Study for Patients with De Novo Primary Hyperparathyroidism. Ann Surg Oncol. 2011;18(6):1723-1728. doi: https:\/\/doi.org\/10.1245\/s10434-010-1507-0","DOI":"10.1245\/s10434-010-1507-0"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun. 2005;26(2):133-136. doi: https:\/\/doi.org\/10.1097\/00006231-200502000-00009","DOI":"10.1097\/00006231-200502000-00009"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Erbil Y, Barbaros U, Salmasl\u00fdoglu A, et al. Value of parathyroid hormone assay for preoperative sonographically guided parathyroid aspirates for minimally invasive parathyroidectomy. J Clin Ultrasound. 2006;34(9):425-429. doi: https:\/\/doi.org\/10.1002\/jcu.20275","DOI":"10.1002\/jcu.20275"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Barczynski M, Golkowski F, Konturek A, et al. Technetium-99msestamibi subtraction scintigraphy vs. ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clin Endocrinol (Oxf ). 2006;65(1):106-113. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02556.x","DOI":"10.1111\/j.1365-2265.2006.02556.x"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Giusti M, Dolcino M, Vera L, et al. Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. J Zhejiang Univ Sci B. 2009;10(5):323-330. doi: https:\/\/doi.org\/10.1631\/jzus.B0820372","DOI":"10.1631\/jzus.B0820372"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Kim IV, Kuznetsov NS, Kuznetsov SN. Study of PTH-FNAB of the Parathyroid Glands as a Method of Topical Diagnosis in Primary Hyperparathyroidism. Endocr Surg. 2014;8(2):14-19. doi: https:\/\/doi.org\/10.14341\/serg2014214-19","DOI":"10.14341\/serg2014214-19"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254-1259. doi: https:\/\/doi.org\/10.1136\/bmj.312.7041.1254","DOI":"10.1136\/bmj.312.7041.1254"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis. 2012;4(5):357-368. doi: https:\/\/doi.org\/10.1177\/1759720X12441869","DOI":"10.1177\/1759720X12441869"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Wood K, Dhital S, Chen H, Sippel RS. What Is the Utility of Distal Forearm DXA in Primary Hyperparathyroidism? Oncologist. 2012;17(3):322-325. doi: https:\/\/doi.org\/10.1634\/theoncologist.2011-0285","DOI":"10.1634\/theoncologist.2011-0285"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Makras P, Anastasilakis AD. Bone disease in primary hyperparathyroidism. Metabolism. 2018;80:57-65. doi: https:\/\/doi.org\/10.1016\/j.metabol.2017.10.003","DOI":"10.1016\/j.metabol.2017.10.003"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Makras P, Anastasilakis AD. Bone disease in primary hyperparathyroidism. Metabolism. 2018;80:57-65. doi: https:\/\/doi.org\/10.1016\/j.metabol.2017.10.003","DOI":"10.1016\/j.metabol.2017.10.003"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Parisien M, Silverberg SJ, Shane E, et al. The Histomorphometry of Bone in Primary Hyperparathyroidism: Preservation of Cancellous Bone Structure*. J Clin Endocrinol Metab. 1990;70(4):930-938. doi: https:\/\/doi.org\/10.1210\/jcem-70-4-930110. Starup-Linde J, Waldhauer E, Rolighed L, et al. Renal stones and","DOI":"10.1210\/jcem-70-4-930"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. Eur J Endocrinol. 2012;166(6):1093-1100. doi: https:\/\/doi.org\/10.1530\/EJE-12-0032","DOI":"10.1530\/EJE-12-0032"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Odvina CV, Sakhaee K, Heller HJ, et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res. 2007;35(3):123-128. doi: https:\/\/doi.org\/10.1007\/s00240-007-0096-2","DOI":"10.1007\/s00240-007-0096-2"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Corbetta S, Baccarelli A, Aroldi A, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest. 2005;28(4):122-128. doi: https:\/\/doi.org\/10.1007\/BF03345354","DOI":"10.1007\/BF03345354"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab. 2011. doi: https:\/\/doi.org\/10.1210\/jc.2011-0569","DOI":"10.1210\/jc.2011-0569"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Frame B. Peptic Ulcer and Hyperparathyroidism. AMA Arch Intern Med. 1960;105(4):536. doi: https:\/\/doi.org\/10.1001\/archinte.1960.00270160034006","DOI":"10.1001\/archinte.1960.00270160034006"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Corleto VD. Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study. J Clin Endocrinol Metab. 1999;84(12):4554-4558. doi: https:\/\/doi.org\/10.1210\/jc.84.12.4554","DOI":"10.1210\/jc.84.12.4554"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Norton JA, Venzon DJ, Berna MJ, et al. Prospective Study of Surgery for Primary Hyperparathyroidism (HPT) in Multiple Endocrine Neoplasia-Type 1 and ZollingerEllison Syndrome. Ann Surg. 2008;247(3):501-510. doi: https:\/\/doi.org\/10.1097\/SLA.0b013e31815efda5","DOI":"10.1097\/SLA.0b013e31815efda5"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Bai HX, Giefer M, Patel M, et al. The Association of Primary Hyperparathyroidism With Pancreatitis. J Clin Gastroenterol. 2012;46(8):656-661. doi: https:\/\/doi.org\/10.1097\/MCG.0b013e31825c446c","DOI":"10.1097\/MCG.0b013e31825c446c"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Silverberg SJ, Shane E, Jacobs TP, et al. A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery. N Engl J Med. 1999;341(17):1249-1255. doi: https:\/\/doi.org\/10.1056\/NEJM199910213411701","DOI":"10.1056\/NEJM199910213411701"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Kouvaraki MA, Greer M, Sharma S, et al. Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: Practice patterns of endocrine surgery. Surgery. 2006;139(4):527-534. doi: https:\/\/doi.org\/10.1016\/j.surg.2005.09.006","DOI":"10.1016\/j.surg.2005.09.006"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Vestergaard P. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003;327(7414):530-534. doi: https:\/\/doi.org\/10.1136\/bmj.327.7414.530","DOI":"10.1136\/bmj.327.7414.530"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Mosekilde L. Fractures in Patients with Primary Hyperparathyroidism: Nationwide Follow-up Study of 1201 Patients. World J Surg. 2003;27(3):343-349. doi: https:\/\/doi.org\/10.1007\/s00268-002-6589-9","DOI":"10.1007\/s00268-002-6589-9"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Khosla S, Melton LJ, Wermers RA, et al. Primary Hyperparathyroidism and the Risk of Fracture: A PopulationBased Study. J Bone Miner Res. 1999;14(10):1700-1707. doi: https:\/\/doi.org\/10.1359\/jbmr.1999.14.10.1700","DOI":"10.1359\/jbmr.1999.14.10.1700"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Tassone F, Guarnieri A, Castellano E, et al. Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(8):3069-3073. doi: https:\/\/doi.org\/10.1210\/jc.2015-2132","DOI":"10.1210\/jc.2015-2132"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Rose DM. Long-term Management and Outcome of Parathyroidectomy for Sporadic Primary MultipleGland Disease. Arch Surg. 2001;136(6):621-626. doi: https:\/\/doi.org\/10.1001\/archsurg.136.6.621","DOI":"10.1001\/archsurg.136.6.621"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Sivula A, Pelkonen R. Long-term Health Risk of Primary Hyperparathyroidism: The Effect of Surgery. Ann Med. 1996;28(2):95-100. doi: https:\/\/doi.org\/10.3109\/07853899609092932","DOI":"10.3109\/07853899609092932"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Norenstedt S, Pernow Y, Brismar K, et al. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013. doi: https:\/\/doi.org\/10.1530\/EJE-13-0547","DOI":"10.1530\/EJE-13-0547"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Bhadada S, Behera A, Shah V, et al. Influence of age and gender on presentation of symptomatic primary hyperparathyroidism. J Postgrad Med. 2012;58(2):107. doi: https:\/\/doi.org\/10.4103\/0022-3859.97171","DOI":"10.4103\/0022-3859.97171"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Silverberg SJ, Brown I, Bilezikian JP. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med. 2002;113(8):681-684. doi: https:\/\/doi.org\/10.1016\/S0002-9343(02)01306-2","DOI":"10.1016\/S0002-9343(02)01306-2"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"VanderWalde LH, Liu I-LA, Haigh PI. Effect of Bone Mineral Density and Parathyroidectomy on Fracture Risk in Primary Hyperparathyroidism. World J Surg. 2009;33(3):406-411. doi: https:\/\/doi.org\/10.1007\/s00268-008-9720-8","DOI":"10.1007\/s00268-008-9720-8"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Fang W-L, Tseng L-M, Chen J-Y, et al. The management of high-risk patients with primary hyperparathyroidism \u2013 minimally invasive parathyroidectomy vs. medical treatment. Clin Endocrinol (Oxf). 2008;68(4):520-528. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03076.x","DOI":"10.1111\/j.1365-2265.2007.03076.x"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized Controlled Clinical Trial of Surgery Versus No Surgery in Patients with Mild Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2004;89(11):5415-5422. doi: https:\/\/doi.org\/10.1210\/jc.2004-0028","DOI":"10.1210\/jc.2004-0028"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Vestergaard P. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598-602. doi: https:\/\/doi.org\/10.1136\/bmj.321.7261.598","DOI":"10.1136\/bmj.321.7261.598"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Bollerslev J, Jansson S, Mollerup CL, et al. Medical Observation, Compared with Parathyroidectomy, for Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial. J Clin Endocrinol Metab. 2007;92(5):1687-1692. doi: https:\/\/doi.org\/10.1210\/jc.2006-1836","DOI":"10.1210\/jc.2006-1836"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155-162. doi: https:\/\/doi.org\/10.1530\/EJE-13-0305","DOI":"10.1530\/EJE-13-0305"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Roschger P, Dempster DW, Zhou H, et al. New Observations on Bone Quality in Mild Primary Hyperparathyroidism as Determined by Quantitative Backscattered Electron Imaging. J Bone Miner Res. 2007;22(5):717-723. doi: https:\/\/doi.org\/10.1359\/jbmr.070120","DOI":"10.1359\/jbmr.070120"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. J Clin Endocrinol Metab. 2007;92(8):3114-3121. doi: https:\/\/doi.org\/10.1210\/jc.2007-0219","DOI":"10.1210\/jc.2007-0219"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Lundstam K, Heck A, Godang K, et al. Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study). J Bone Miner Res. 2017;32(9):1907-1914. doi: https:\/\/doi.org\/10.1002\/jbmr.3177","DOI":"10.1002\/jbmr.3177"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Mosekilde L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. J Intern Med. 2004;255(1):108-114. doi: https:\/\/doi.org\/10.1046\/j.0954-6820.2003.01237.x","DOI":"10.1046\/j.0954-6820.2003.01237.x"},{"key":"ref139","unstructured":"Peacock, M., Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2002;17:87-94."},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Salahudeen AK, Thomas TH, Sellars L, et al. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci. 1989;76(3):289-296. doi: https:\/\/doi.org\/10.1042\/cs0760289","DOI":"10.1042\/cs0760289"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Mollerup CL. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ. 2002;325(7368):807-807. doi: https:\/\/doi.org\/10.1136\/bmj.325.7368.807","DOI":"10.1136\/bmj.325.7368.807"},{"key":"ref142","unstructured":"Deaconson TF, Wilson SD, Jacob L. The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery. 1987. doi: https:\/\/doi.org\/10.5555\/uri:pii:0039606087903163"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Hedb\u00e4ck G, Abrahamsson K, Od\u00e9n A. The improvement of renal concentration capacity after surgery for primary hyperparathyroidism. Eur J Clin Invest. 2001;31(12):1048-1053. doi: https:\/\/doi.org\/10.1046\/j.1365-2362.2001.00926.x","DOI":"10.1046\/j.1365-2362.2001.00926.x"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Sejean K, Calmus S, Durand-Zaleski I, et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Eur J Endocrinol. 2005;153(6):915-927. doi: https:\/\/doi.org\/10.1530\/eje.1.02029","DOI":"10.1530\/eje.1.02029"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery. 2006;140(6):874-882. doi: https:\/\/doi.org\/10.1016\/j.surg.2006.07.032","DOI":"10.1016\/j.surg.2006.07.032"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Zanocco K, Sturgeon C. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery. 2008;144(2):290-298. doi: https:\/\/doi.org\/10.1016\/j.surg.2008.03.044","DOI":"10.1016\/j.surg.2008.03.044"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Udelsman R, \u00c5kerstr\u00f6m G, Biagini C, et al. The Surgical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3595-3606. doi: https:\/\/doi.org\/10.1210\/jc.2014-2000","DOI":"10.1210\/jc.2014-2000"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Mittendorf EA, Wefel JS, Meyers CA, et al. Improvement of Sleep Disturbance and Neurocognitive Function after Parathyroidectomy in Patients with Primary Hyperparathyroidism. Endocr Pract. 2007;13(4):338-344. doi: https:\/\/doi.org\/10.4158\/EP.13.4.338","DOI":"10.4158\/EP.13.4.338"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Udelsman R, Lin Z, Donovan P. The Superiority of Minimally Invasive Parathyroidectomy Based on 1650 Consecutive Patients With Primary Hyperparathyroidism. Ann Surg. 2011;253(3):585-591. doi: https:\/\/doi.org\/10.1097\/SLA.0b013e318208fed9","DOI":"10.1097\/SLA.0b013e318208fed9"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Venkat R, Kouniavsky G, Tufano RP, et al. Long-Term Outcome in Patients with Primary Hyperparathyroidism who Underwent Minimally Invasive Parathyroidectomy. World J Surg. 2012;36(1):55-60. doi: https:\/\/doi.org\/10.1007\/s00268-011-1344-8","DOI":"10.1007\/s00268-011-1344-8"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Suliburk JW, Sywak MS, Sidhu SB, Delbridge LW. 1000 minimally invasive parathyroidectomies without intra-operative parathyroid hormone measurement: lessons learned. ANZ J Surg. 2011;81(5):362-365. doi: https:\/\/doi.org\/10.1111\/j.1445-2197.2010.05488.x","DOI":"10.1111\/j.1445-2197.2010.05488.x"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Aspinall SR, Boase S, Malycha P. Long-Term Symptom Relief from Primary Hyperparathyroidism Following Minimally Invasive Parathyroidectomy. World J Surg. 2010;34(9):2223-2227. doi: https:\/\/doi.org\/10.1007\/s00268-010-0687-x","DOI":"10.1007\/s00268-010-0687-x"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Lombardi CP, Raffaelli M, Traini E, et al. Video-Assisted Minimally Invasive Parathyroidectomy: Benefits and Long-Term Results. World J Surg. 2009;33(11):2266-2281. doi: https:\/\/doi.org\/10.1007\/s00268-009-9931-7","DOI":"10.1007\/s00268-009-9931-7"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"Allendorf J, DiGorgi M, Spanknebel K, et al. 1112 Consecutive Bilateral Neck Explorations for Primary Hyperparathyroidism. World J Surg. 2007;31(11):2075-2080. doi: https:\/\/doi.org\/10.1007\/s00268-007-9068-5","DOI":"10.1007\/s00268-007-9068-5"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Abdulla AG, Ituarte PHG, Harari A, et al. Trends in the Frequency and Quality of Parathyroid Surgery. Ann Surg. 2015;261(4):746-750. doi: https:\/\/doi.org\/10.1097\/SLA.0000000000000812","DOI":"10.1097\/SLA.0000000000000812"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"McGill J, Sturgeon C, Kaplan SP, et al. How Does the Operative Strategy for Primary Hyperparathyroidism Impact the Findings and Cure Rate? A Comparison of 800 Parathyroidectomies. J Am Coll Surg. 2008;207(2):246-249. doi: https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.01.066","DOI":"10.1016\/j.jamcollsurg.2008.01.066"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"J\u00e4rhult J, Ander S, Asking B, et al. Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg. 2010;97(11):1680-1685. doi: https:\/\/doi.org\/10.1002\/bjs.7199","DOI":"10.1002\/bjs.7199"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Marti JL, Yang CS, Carling T, et al. Surgical Approach and Outcomes in Patients with Lithium-Associated Hyperparathyroidism. Ann Surg Oncol. 2012;19(11):3465-3471. doi: https:\/\/doi.org\/10.1245\/s10434-012-2367-6","DOI":"10.1245\/s10434-012-2367-6"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"Irvin GL, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg. 1991;162(4):299-302. doi: https:\/\/doi.org\/10.1016\/0002-9610(91)90135-Z","DOI":"10.1016\/0002-9610(91)90135-Z"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Irvin GL, Carneiro DM, Solorzano CC. Progress in the Operative Management of Sporadic Primary Hyperparathyroidism Over 34 Years. Ann Surg. 2004;239(5):704-711. doi: https:\/\/doi.org\/10.1097\/01.sla.0000124448.49794.74","DOI":"10.1097\/01.sla.0000124448.49794.74"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Woodrum DT, Saunders BD, England BG, et al. The influence of sample site on intraoperative PTH monitoring during parathyroidectomy. Surgery. 2004;136(6):1169-1175. doi: https:\/\/doi.org\/10.1016\/j.surg.2004.06.043","DOI":"10.1016\/j.surg.2004.06.043"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Kuznetsov NS, Kim IV, Kuznetsov SN. Intraoperative parathyroid hormone in strategy of surgical treatment of a primary hyperparathyreosis. Endocrine Surgery. 2011;5(2):18-25. (In Russ.) doi: https:\/\/doi.org\/10.14341\/2306-3513-2011-2-18-25","DOI":"10.14341\/2306-3513-2011-2-18-25"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbeck\u2019s Arch Surg. 2009;394(5):843-849. doi: https:\/\/doi.org\/10.1007\/s00423-009-0510-z","DOI":"10.1007\/s00423-009-0510-z"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Miura D, Wada N, Arici C, et al. Does Intraoperative Quick Parathyroid Hormone Assay Improve the Results of Parathyroidectomy? World J Surg. 2002;26(8):926-930. doi: https:\/\/doi.org\/10.1007\/s00268-002-6620-1","DOI":"10.1007\/s00268-002-6620-1"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Gawande AA. Reassessment of Parathyroid Hormone Monitoring During Parathyroidectomy for Primary Hyperparathyroidism After 2 Preoperative Localization Studies. Arch Surg. 2006;141(4):381. doi: https:\/\/doi.org\/10.1001\/archsurg.141.4.381","DOI":"10.1001\/archsurg.141.4.381"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"Kald BA, Heath DI, Lausen I, Mollerup CL. Risk Assessment for Severe Postoperative Hypocalcaemia after Neck Exploration for Primary Hyperparathyroidism. Scand J Surg. 2005;94(3):216-220. doi: https:\/\/doi.org\/10.1177\/145749690509400308","DOI":"10.1177\/145749690509400308"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Mittendorf, EA, Merlino JI, McHenry CR. Post-Parathyroidectomy Hypocalcemia: Incidence, Risk Factors, and Management\/DISCUSSION. The American surgeon, 2004;70(2);114-119.","DOI":"10.1177\/000313480407000204"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"Stewart ZA, Blackford A, Somervell H, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005;138(6):1018-1026. doi: https:\/\/doi.org\/10.1016\/j.surg.2005.09.018","DOI":"10.1016\/j.surg.2005.09.018"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Strickland PL, Recabaren J. Are preoperative serum calcium, parathyroid hormone, and adenoma weight predictive of postoperative hypocalcemia? The American surgeon, 2002;68(12):1080-1082.","DOI":"10.1177\/000313480206801211"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral Versus Bilateral Neck Exploration for Primary Hyperparathyroidism. Ann Surg. 2002;236(5):543-551. doi: https:\/\/doi.org\/10.1097\/00000658-200211000-00001","DOI":"10.1097\/00000658-200211000-00001"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"Roman SA, Sosa JA, Pietrzak RH, et al. The Effects of Serum Calcium and Parathyroid Hormone Changes on Psychological and Cognitive Function in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism. Ann Surg. 2011;253(1):131-137. doi: https:\/\/doi.org\/10.1097\/SLA.0b013e3181f66720","DOI":"10.1097\/SLA.0b013e3181f66720"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Sperlongano P, Sperlongano S, Foroni F, et al. Postoperative hypocalcemia: Assessment timing. Int J Surg. 2014;12:S95-S97. doi: https:\/\/doi.org\/10.1016\/j.ijsu.2014.05.042","DOI":"10.1016\/j.ijsu.2014.05.042"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"Sinha S, Baskota DK. Comparison of corrected serum calcium changes following thyroid and non thyroid neck surgeries. Nepal J ENT Head Neck Surg. 2018;6(1):1-4. doi: https:\/\/doi.org\/10.3126\/njenthns.v6i1.19430","DOI":"10.3126\/njenthns.v6i1.19430"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"Bergenfelz A, Kanngiesser V, Zielke A, et al. Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005;92(2):190-197. doi: https:\/\/doi.org\/10.1002\/bjs.4814","DOI":"10.1002\/bjs.4814"},{"key":"ref175","doi-asserted-by":"crossref","unstructured":"Witteveen JE, van Thiel S, Romijn JA, Hamdy NAT. Therapy of endocrine disease: Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45-R53. doi: https:\/\/doi.org\/10.1530\/EJE-12-0528","DOI":"10.1530\/EJE-12-0528"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"Mitchell DM, Regan S, Cooley MR, et al. Long-Term Follow-Up of Patients with Hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507-4514. doi: https:\/\/doi.org\/10.1210\/jc.2012-1808","DOI":"10.1210\/jc.2012-1808"},{"key":"ref177","doi-asserted-by":"crossref","unstructured":"Puzziello A, Rosato L, Innaro N, et al. Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine. 2014;47(2):537-542. doi: https:\/\/doi.org\/10.1007\/s12020-014-0209-y","DOI":"10.1007\/s12020-014-0209-y"},{"key":"ref178","doi-asserted-by":"crossref","unstructured":"Khan MI, Waguespack SG, Hu MI. Medical Management Of Postsurgical Hypoparathyroidism. Endocr Pract. 2011;17:18-25. doi: https:\/\/doi.org\/10.4158\/EP10302.RA","DOI":"10.4158\/EP10302.RA"},{"key":"ref179","doi-asserted-by":"crossref","unstructured":"Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. QJM. 2011;104(6):513-521. doi: https:\/\/doi.org\/10.1093\/qjmed\/hcq261","DOI":"10.1093\/qjmed\/hcq261"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"Rubin MR, Bilezikian JP, McMahon DJ, et al. The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. J Clin Endocrinol Metab. 2008;93(9):3462-3470. doi: https:\/\/doi.org\/10.1210\/jc.2007-1215","DOI":"10.1210\/jc.2007-1215"},{"key":"ref181","doi-asserted-by":"crossref","unstructured":"Cassibba S, Pellegrino M, Gianotti L, et al. Silent Renal Stones in Primary Hyperparathyroidism: Prevalence and Clinical Features. Endocr Pract. 2014;20(11):1137-1142. doi: https:\/\/doi.org\/10.4158\/EP14074.OR","DOI":"10.4158\/EP14074.OR"},{"key":"ref182","doi-asserted-by":"crossref","unstructured":"Majid H, Khan AH, Riaz M, et al. Identifying Parathyroid Hormone Disorders and their Phenotypes through a Bone Health Screening Panel: It\u2019s not Simple Vitamin D Deficiency! Endocr Pract. 2016;22(7):814-821. doi: https:\/\/doi.org\/10.4158\/EP161206.OR","DOI":"10.4158\/EP161206.OR"},{"key":"ref183","doi-asserted-by":"crossref","unstructured":"Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr. 2011;14(5):938-939. doi: https:\/\/doi.org\/10.1017\/S1368980011000565","DOI":"10.1017\/S1368980011000565"},{"key":"ref184","doi-asserted-by":"crossref","unstructured":"Locker, RN, EdD FG, Silverberg, et al. Optimal Dietary Calcium Intake in Primary Hyperparathyroidism. Am J Med. 1997;102(6):543-550. doi: https:\/\/doi.org\/10.1016\/S0002-9343(97)00053-3","DOI":"10.1016\/S0002-9343(97)00053-3"},{"key":"ref185","doi-asserted-by":"crossref","unstructured":"Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr. 2002;41(6):258-263. doi: https:\/\/doi.org\/10.1007\/s00394-002-0383-1","DOI":"10.1007\/s00394-002-0383-1"},{"key":"ref186","doi-asserted-by":"crossref","unstructured":"Riss P, Kammer M, Selberherr A, et al. The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf ). 2016;85(2):196-201. doi: https:\/\/doi.org\/10.1111\/cen.13046","DOI":"10.1111\/cen.13046"},{"key":"ref187","doi-asserted-by":"crossref","unstructured":"Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism\u2014A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017;102(4):1270-1276. doi: https:\/\/doi.org\/10.1210\/jc.2016-2481","DOI":"10.1210\/jc.2016-2481"},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"Szmidt J. Reoperations for Persistent or Recurrent Primary Hyperparathyroidism: Results of a Retrospective Cohort Study at a Tertiary Referral Center. Med Sci Monit. 2014;20:1604-1612. doi: https:\/\/doi.org\/10.12659\/MSM.890983","DOI":"10.12659\/MSM.890983"},{"key":"ref189","doi-asserted-by":"crossref","unstructured":"Udelsman R. Approach to the Patient with Persistent or Recurrent Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2011;96(10):2950-2958. doi: https:\/\/doi.org\/10.1210\/jc.2011-1010","DOI":"10.1210\/jc.2011-1010"},{"key":"ref190","unstructured":"Akerstrom G. Current controversy in parathyroid operation and reoperation. Parathyroid pathology, 1994: P. 23-41."},{"key":"ref191","doi-asserted-by":"crossref","unstructured":"Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016;151(10):959-968. doi: https:\/\/doi.org\/10.1001\/jamasurg.2016.2310","DOI":"10.1001\/jamasurg.2016.2310"},{"key":"ref192","doi-asserted-by":"crossref","unstructured":"McDow AD, Sippel RS. Should Symptoms Be Considered an Indication for Parathyroidectomy in Primary Hyperparathyroidism? Clin Med Insights Endocrinol Diabetes. 2018;11:117955141878513. doi: https:\/\/doi.org\/10.1177\/1179551418785135","DOI":"10.1177\/1179551418785135"},{"key":"ref193","doi-asserted-by":"crossref","unstructured":"Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical Management of Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10):3607-3618. doi: https:\/\/doi.org\/10.1210\/jc.2014-1417","DOI":"10.1210\/jc.2014-1417"},{"key":"ref194","doi-asserted-by":"crossref","unstructured":"Sankaran S, Gamble G, Bolland M, et al. Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A MetaAnalysis. J Clin Endocrinol Metab. 2010;95(4):1653-1662. doi: https:\/\/doi.org\/10.1210\/jc.2009-2384","DOI":"10.1210\/jc.2009-2384"},{"key":"ref195","doi-asserted-by":"crossref","unstructured":"Khan A, Bilezikian J, Bone H, et al. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015;172(5):527-535. doi: https:\/\/doi.org\/10.1530\/EJE-14-0877","DOI":"10.1530\/EJE-14-0877"},{"key":"ref196","doi-asserted-by":"crossref","unstructured":"Leere JS, Karmisholt J, Robaczyk M, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407-417. doi: https:\/\/doi.org\/10.1016\/S2213-8587(20)30063-2","DOI":"10.1016\/S2213-8587(20)30063-2"},{"key":"ref197","doi-asserted-by":"crossref","unstructured":"Cesareo R, Di Stasio E, Vescini F, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2015;26(4):1295-1302. doi: https:\/\/doi.org\/10.1007\/s00198-014-3000-2","DOI":"10.1007\/s00198-014-3000-2"},{"key":"ref198","doi-asserted-by":"crossref","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin Proc. 2008;83(9):1032-1045. doi: https:\/\/doi.org\/10.4065\/83.9.1032","DOI":"10.4065\/83.9.1032"},{"key":"ref199","doi-asserted-by":"crossref","unstructured":"Segula D, Nikolova T, Marks E, et al. Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism. Int J Clin Med. 2014;05(14):829-835. doi: https:\/\/doi.org\/10.4236\/ijcm.2014.514111","DOI":"10.4236\/ijcm.2014.514111"},{"key":"ref200","doi-asserted-by":"crossref","unstructured":"Yeh MW, Zhou H, Adams AL, et al. The Relationship of Parathyroidectomy and Bisphosphonates With Fracture Risk in Primary Hyperparathyroidism. Ann Intern Med. 2016;164(11):715-723. doi: https:\/\/doi.org\/10.7326\/M15-1232","DOI":"10.7326\/M15-1232"},{"key":"ref201","doi-asserted-by":"crossref","unstructured":"Vera L, Accornero M, Dolcino M, et al. Pierwotna nadczynno\u015b\u0107 przytarczyc o niewielkim nasileniu \u2014 por\u00f3wnanie leczenia farmakologicznego i obserwacji klinicznej w ramach trwaj\u0105cego pi\u0119\u0107 lat badania klinicznego. Endokrynol Pol. 2015;65(6):456-463. doi: https:\/\/doi.org\/10.5603\/EP.2014.0063","DOI":"10.5603\/EP.2014.0063"},{"key":"ref202","doi-asserted-by":"crossref","unstructured":"Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ. Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response\u2013Based Meta-Analysis. J Clin Endocrinol Metab. 2014;99(10):3746-3755. doi: https:\/\/doi.org\/10.1210\/jc.2013-3795","DOI":"10.1210\/jc.2013-3795"},{"key":"ref203","doi-asserted-by":"crossref","unstructured":"Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study. J Clin Endocrinol Metab. 2009;94(12):4860-4867. doi: https:\/\/doi.org\/10.1210\/jc.2009-1472","DOI":"10.1210\/jc.2009-1472"},{"key":"ref204","doi-asserted-by":"crossref","unstructured":"Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf ). 2014;80(6):797-803. doi: https:\/\/doi.org\/10.1111\/cen.12398","DOI":"10.1111\/cen.12398"},{"key":"ref205","doi-asserted-by":"crossref","unstructured":"Norenstedt S, Pernow Y, Zedenius J, et al. Vitamin D Supplementation After Parathyroidectomy: Effect on Bone Mineral Density\u2014A Randomized Double\u2010Blind Study. J Bone Miner Res. 2014;29(4):960-967. doi: https:\/\/doi.org\/10.1002\/jbmr.2102","DOI":"10.1002\/jbmr.2102"},{"key":"ref206","doi-asserted-by":"crossref","unstructured":"Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-2072. doi: https:\/\/doi.org\/10.1172\/JCI29449","DOI":"10.1172\/JCI29449"},{"key":"ref207","doi-asserted-by":"crossref","unstructured":"Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28. doi: https:\/\/doi.org\/10.1093\/ajcn\/84.1.18","DOI":"10.1093\/ajcn\/84.1.18"},{"key":"ref208","doi-asserted-by":"crossref","unstructured":"Westerdahl J. Risk Factors for Postoperative Hypocalcemia After Surgery for Primary Hyperparathyroidism. Arch Surg. 2000;135(2):142-147. doi: https:\/\/doi.org\/10.1001\/archsurg.135.2.142","DOI":"10.1001\/archsurg.135.2.142"},{"key":"ref209","doi-asserted-by":"crossref","unstructured":"Carty SE, Roberts MM, Virji MA, et al. Elevated serum parathormone level after \u201cconcise parathyroidectomy\u201d for primary sporadic hyperparathyroidism. Surgery. 2002;132(6):1086-1093. doi: https:\/\/doi.org\/10.1067\/msy.2002.128479","DOI":"10.1067\/msy.2002.128479"},{"key":"ref210","doi-asserted-by":"crossref","unstructured":"Carneiro DM, Irvin GL. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery. 2000;128(6):925-929. doi: https:\/\/doi.org\/10.1067\/msy.2000.109964","DOI":"10.1067\/msy.2000.109964"},{"key":"ref211","doi-asserted-by":"crossref","unstructured":"Beyer TD, Solorzano CC, Prinz RA, et al. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery. 2007;141(6):777-783. doi: https:\/\/doi.org\/10.1016\/j.surg.2007.01.025","DOI":"10.1016\/j.surg.2007.01.025"},{"key":"ref212","doi-asserted-by":"crossref","unstructured":"Kantorovich V, Gacad MA, Seeger LL, Adams JS. Bone Mineral Density Increases with Vitamin D Repletion in Patients with Coexistent Vitamin D Insufficiency and Primary Hyperparathyroidism 1. J Clin Endocrinol Metab. 2000;85(10):3541-3543. doi: https:\/\/doi.org\/10.1210\/jcem.85.10.6909","DOI":"10.1210\/jcem.85.10.6909"},{"key":"ref213","doi-asserted-by":"crossref","unstructured":"Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic Crisis: A Clinical Review. Am J Med. 2015;128(3):239-245. doi: https:\/\/doi.org\/10.1016\/j.amjmed.2014.09.030","DOI":"10.1016\/j.amjmed.2014.09.030"},{"key":"ref214","doi-asserted-by":"crossref","unstructured":"Schweitzer VG. Management of Severe Hypercalcemia Caused by Primary Hyperparathyroidism. Arch Surg. 1978;113(4):373-381. doi: https:\/\/doi.org\/10.1001\/archsurg.1978.01370160031004","DOI":"10.1001\/archsurg.1978.01370160031004"},{"key":"ref215","doi-asserted-by":"crossref","unstructured":"Cannon J, Lew JI, Sol\u00f3rzano CC. Parathyroidectomy for hypercalcemic crisis: 40 years\u2019 experience and long-term outcomes. Surgery. 2010;148(4):807-813. doi: https:\/\/doi.org\/10.1016\/j.surg.2010.07.041","DOI":"10.1016\/j.surg.2010.07.041"},{"key":"ref216","doi-asserted-by":"crossref","unstructured":"Phitayakorn R, McHenry CR. Hyperparathyroid Crisis: Use of Bisphosphonates as a Bridge to Parathyroidectomy. J Am Coll Surg. 2008;206(6):1106-1115. doi: https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.11.010","DOI":"10.1016\/j.jamcollsurg.2007.11.010"},{"key":"ref217","doi-asserted-by":"crossref","unstructured":"Starker LF, Bj\u00f6rklund P, Theoharis C, et al. Clinical and Histopathological Characteristics of Hyperparathyroidisminduced Hypercalcemic Crisis. World J Surg. 2011;35(2):331-335. doi: https:\/\/doi.org\/10.1007\/s00268-010-0840-6","DOI":"10.1007\/s00268-010-0840-6"},{"key":"ref218","doi-asserted-by":"crossref","unstructured":"Beck W, Lew JI, Sol\u00f3rzano CC. Hypercalcemic Crisis in the Era of Targeted Parathyroidectomy. J Surg Res. 2011;171(2):404-408. doi: https:\/\/doi.org\/10.1016\/j.jss.2011.04.010","DOI":"10.1016\/j.jss.2011.04.010"},{"key":"ref219","doi-asserted-by":"crossref","unstructured":"Wood AJJ, Bilezikian JP. Management of Acute Hypercalcemia. N Engl J Med. 1992;326(18):1196-1203. doi: https:\/\/doi.org\/10.1056\/NEJM199204303261806","DOI":"10.1056\/NEJM199204303261806"},{"key":"ref220","unstructured":"Gurrado, A., et al. Hypercalcaemic crisis due to primary hyperparathyroidism\u2014a systematic literature review and case report. Endokrynologia Polska. 2012;63(6):494-502."},{"key":"ref221","doi-asserted-by":"crossref","unstructured":"Carroll R, Matfin G. Review: Endocrine and metabolic emergencies: hypercalcaemia. Ther Adv Endocrinol Metab. 2010;1(5):225-234. doi: https:\/\/doi.org\/10.1177\/2042018810390260","DOI":"10.1177\/2042018810390260"},{"key":"ref222","doi-asserted-by":"crossref","unstructured":"Eremkina A, Krupinova J, Dobreva E, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect. 2020;9(10):1019-1027. doi: https:\/\/doi.org\/10.1530\/EC-20-0380","DOI":"10.1530\/EC-20-0380"},{"key":"ref223","doi-asserted-by":"crossref","unstructured":"Pekkolay Z, Kilin\u00e7 F, Soylu H, et al. Preoperative Parenteral \u0130bandronate for Treating Severe Hypercalcemia Associated with Primary Hyperparathyroidism: An Effective and Cheap Drug. Turkish J Endocrinol Metab. 2018;22(2):39-41. doi: https:\/\/doi.org\/10.25179\/tjem.20182202-P087","DOI":"10.25179\/tjem.20182202-P087"},{"key":"ref224","doi-asserted-by":"crossref","unstructured":"Abdelhadi M, Nordenstr\u00f6m J. Bone Mineral Recovery after Parathyroidectomy in Patients with Primary and Renal Hyperparathyroidism. J Clin Endocrinol Metab. 1998;83(11):3845-3851. doi: https:\/\/doi.org\/10.1210\/jcem.83.11.5249","DOI":"10.1210\/jcem.83.11.5249"},{"key":"ref225","doi-asserted-by":"crossref","unstructured":"Nakaoka D, Sugimoto T, Kobayashi T, et al. Evaluation of Changes in Bone Density and Biochemical Parameters after Parathyroidectomy in Primary Hyperparathyroidism. Endocr J. 2000;47(3):231-237. doi: https:\/\/doi.org\/10.1507\/endocrj.47.231","DOI":"10.1507\/endocrj.47.231"},{"key":"ref226","doi-asserted-by":"crossref","unstructured":"Nordenstr\u00f6m E, Westerdahl J, Bergenfelz A. Recovery of Bone Mineral Density in 126 Patients after Surgery for Primary Hyperparathyroidism. World J Surg. 2004;28(5):502-507. doi: https:\/\/doi.org\/10.1007\/s00268-004-7274-y","DOI":"10.1007\/s00268-004-7274-y"},{"key":"ref227","doi-asserted-by":"crossref","unstructured":"Brandi ML, Gagel RF, Angeli A, et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab. 2001;86(12):5658-5671. doi: https:\/\/doi.org\/10.1210\/jcem.86.12.8070","DOI":"10.1210\/jcem.86.12.8070"},{"key":"ref228","doi-asserted-by":"crossref","unstructured":"Lassen T, Friis-Hansen L, Rasmussen \u00c5K, et al. Primary Hyperparathyroidism in Young People. When Should We Perform Genetic Testing for Multiple Endocrine Neoplasia 1 (MEN-1)? J Clin Endocrinol Metab. 2014;99(11):3983-3987. doi: https:\/\/doi.org\/10.1210\/jc.2013-4491","DOI":"10.1210\/jc.2013-4491"},{"key":"ref229","doi-asserted-by":"crossref","unstructured":"Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349-359. doi: https:\/\/doi.org\/10.1007\/s12020-017-1234-4","DOI":"10.1007\/s12020-017-1234-4"},{"key":"ref230","doi-asserted-by":"crossref","unstructured":"Sakurai A, Suzuki S, Kosugi S, et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf ). 2012;76(4):533-539. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04227.x","DOI":"10.1111\/j.1365-2265.2011.04227.x"},{"key":"ref231","doi-asserted-by":"crossref","unstructured":"Manoharan J, Raue F, Lopez CL, et al. Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary? World J Surg. 2017;41(8):2026-2032. doi: https:\/\/doi.org\/10.1007\/s00268-017-3992-9","DOI":"10.1007\/s00268-017-3992-9"},{"key":"ref232","doi-asserted-by":"crossref","unstructured":"Goudet P, Murat A, Binquet C, et al. Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d\u2019Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients. World J Surg. 2010;34(2):249-255. doi: https:\/\/doi.org\/10.1007\/s00268-009-0290-1","DOI":"10.1007\/s00268-009-0290-1"},{"key":"ref233","doi-asserted-by":"crossref","unstructured":"Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary Tumors and Hyperplasia in Multiple Endocrine Neoplasia Type 1 Syndrome (MEN1): A Case-Control Study in a Series of 77 Patients Versus 2509 Non-MEN1 Patients. Am J Surg Pathol. 2008;32(4):534-543. doi: https:\/\/doi.org\/10.1097\/PAS.0b013e31815ade45","DOI":"10.1097\/PAS.0b013e31815ade45"},{"key":"ref234","doi-asserted-by":"crossref","unstructured":"Gibril F, Venzon DJ, Ojeaburu JV, et al. Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form. J Clin Endocrinol Metab. 2001;86(11):5282-5293. doi: https:\/\/doi.org\/10.1210\/jcem.86.11.8011","DOI":"10.1210\/jcem.86.11.8011"},{"key":"ref235","doi-asserted-by":"crossref","unstructured":"Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1- Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity. J Bone Miner Res. 2009;24(8):1404-1410. doi: https:\/\/doi.org\/10.1359\/jbmr.090304","DOI":"10.1359\/jbmr.090304"},{"key":"ref236","doi-asserted-by":"crossref","unstructured":"Hosking SW, Jones H, Du Boulay CEH, McGinn FP. Surgery for parathyroid adenoma and hyperplasia: Relationship of histology to outcome. Head Neck. 1993;15(1):24-28. doi: https:\/\/doi.org\/10.1002\/hed.2880150106","DOI":"10.1002\/hed.2880150106"},{"key":"ref237","doi-asserted-by":"crossref","unstructured":"Machens A, Schaaf L, Karges W, et al. Age\u2010related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clinical endocrinology, 2007;67(4):613-622. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02934.x","DOI":"10.1111\/j.1365-2265.2007.02934.x"},{"key":"ref238","doi-asserted-by":"crossref","unstructured":"Schaaf L, Pickel J, Zinner K, et al. Developing Effective Screening Strategies in Multiple Endocrine Neoplasia Type 1 (MEN 1) on the Basis of Clinical and Sequencing Data of German Patients with MEN 1. Exp Clin Endocrinol Diabetes. 2007;115(08):509-517. doi: https:\/\/doi.org\/10.1055\/s-2007-970160","DOI":"10.1055\/s-2007-970160"},{"key":"ref239","doi-asserted-by":"crossref","unstructured":"Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders*. J Intern Med. 2005;257(1):27-37. doi: https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01428.x","DOI":"10.1111\/j.1365-2796.2004.01428.x"},{"key":"ref240","unstructured":"Rostomyan LG. Sindrom mnozhestvennykh endokrinnykh neoplazii 1 tipa: rasprostranennost\u2019 sredi patsientov s pervichnym giperparatireozom, klinicheskie i molekulyarno-geneticheskie kharakteristiki. [dissertation] Moscow; 2011. (In Russ.)"},{"key":"ref241","doi-asserted-by":"crossref","unstructured":"Goudet P, Dalac A, Le Bras M, et al. MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d\u2019\u00e9tude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577. doi: https:\/\/doi.org\/10.1210\/jc.2014-3659","DOI":"10.1210\/jc.2014-3659"},{"key":"ref242","doi-asserted-by":"crossref","unstructured":"Mamedova EO, Mokrysheva NG, Pigarova EA, et al. Molecular and genetic features of primary hyperparathyroidism in young patients. Problems of Endocrinology. 2016;62(2):4-11. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl20166224-11","DOI":"10.14341\/probl20166224-11"},{"key":"ref243","doi-asserted-by":"crossref","unstructured":"Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2003;134(6):858-864. doi: https:\/\/doi.org\/10.1016\/S0039-6060(03)00406-9","DOI":"10.1016\/S0039-6060(03)00406-9"},{"key":"ref244","doi-asserted-by":"crossref","unstructured":"Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery. 2014;156(6):1326-1335. doi: https:\/\/doi.org\/10.1016\/j.surg.2014.08.006","DOI":"10.1016\/j.surg.2014.08.006"},{"key":"ref245","doi-asserted-by":"crossref","unstructured":"Pieterman CRC, van Hulsteijn LT, den Heijer M, et al. Primary Hyperparathyroidism in MEN1 Patients. Ann Surg. 2012;255(6):1171-1178. doi: https:\/\/doi.org\/10.1097\/SLA.0b013e31824c5145","DOI":"10.1097\/SLA.0b013e31824c5145"},{"key":"ref246","doi-asserted-by":"crossref","unstructured":"Lambert LA. Surgical Treatment of Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 1. Arch Surg. 2005;140(4):374. doi: https:\/\/doi.org\/10.1001\/archsurg.140.4.374","DOI":"10.1001\/archsurg.140.4.374"},{"key":"ref247","doi-asserted-by":"crossref","unstructured":"Balsalobre Salmeron MD, Rodriguez Gonzalez JM, Sancho Fornos J, et al. Causes and Treatment of Recurrent Hyperparathyroidism After Subtotal Parathyroidectomy in the Presence of Multiple Endocrine Neoplasia 1. World J Surg. 2010;34(6):1325-1331. doi: https:\/\/doi.org\/10.1007\/s00268-010-0605-2","DOI":"10.1007\/s00268-010-0605-2"},{"key":"ref248","doi-asserted-by":"crossref","unstructured":"Lairmore TC, Piersall LD, DeBenedetti MK, et al. Clinical Genetic Testing and Early Surgical Intervention in Patients With Multiple Endocrine Neoplasia Type 1 (MEN 1). Ann Surg. 2004;239(5):637-647. doi: https:\/\/doi.org\/10.1097\/01.sla.0000124383.98416.8d","DOI":"10.1097\/01.sla.0000124383.98416.8d"},{"key":"ref249","doi-asserted-by":"crossref","unstructured":"Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d\u2019\u00e9tude des Tumeurs Endocrines database. Eur J Endocrinol. 2012;166(2):269-279. doi: https:\/\/doi.org\/10.1530\/EJE-11-0679","DOI":"10.1530\/EJE-11-0679"},{"key":"ref250","doi-asserted-by":"crossref","unstructured":"Yip L. Multiple Endocrine Neoplasia Type 2. Arch Surg. 2003;138(4):409-416. doi: https:\/\/doi.org\/10.1001\/archsurg.138.4.409","DOI":"10.1001\/archsurg.138.4.409"},{"key":"ref251","doi-asserted-by":"crossref","unstructured":"Voss RK, Feng L, Lee JE, et al. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017;102(8):2807-2813. doi: https:\/\/doi.org\/10.1210\/jc.2017-00317","DOI":"10.1210\/jc.2017-00317"},{"key":"ref252","doi-asserted-by":"crossref","unstructured":"Lairmore TC, Ball DW, Baylin SB, Wells SA. Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes. Ann Surg. 1993;217(6):595-603. doi: https:\/\/doi.org\/10.1097\/00000658-199306000-00001","DOI":"10.1097\/00000658-199306000-00001"},{"key":"ref253","doi-asserted-by":"crossref","unstructured":"Larsen LV, Mirebeau-Prunier D, Imai T, et al. Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocr Connect. 2020;9(6):489-497. doi: https:\/\/doi.org\/10.1530\/EC-20-0163","DOI":"10.1530\/EC-20-0163"},{"key":"ref254","doi-asserted-by":"crossref","unstructured":"Scholten A, Schreinemakers JMJ, Pieterman CRC, et al. Evolution of Surgical Treatment of Primary Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 2A. Endocr Pract. 2011;17(1):7-15. doi: https:\/\/doi.org\/10.4158\/EP10050.OR","DOI":"10.4158\/EP10050.OR"},{"key":"ref255","doi-asserted-by":"crossref","unstructured":"Keiser HR. Sipple\u2019s Syndrome: Medullary Thyroid Carcinoma, Pheochromocytoma, and Parathyroid Disease. Ann Intern Med. 1973;78(4):561. doi: https:\/\/doi.org\/10.7326\/0003-4819-78-4-561","DOI":"10.7326\/0003-4819-78-4-561"},{"key":"ref256","unstructured":"Kraimps JL, Duh QY, Demeure M, Clark OH. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112(6):1080-1088. doi: https:\/\/doi.org\/10.5555\/uri:pii:003960609290311M"},{"key":"ref257","doi-asserted-by":"crossref","unstructured":"Herfarth KKF, Bartsch D, Doherty GM, et al. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery. 1996;120(6):966-974. doi: https:\/\/doi.org\/10.1016\/S0039-6060(96)80042-0","DOI":"10.1016\/S0039-6060(96)80042-0"},{"key":"ref258","doi-asserted-by":"crossref","unstructured":"Kraimps J-L, Denizot A, Carnaille B, et al. Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type IIa: Retrospective French Multicentric Study. World J Surg. 1996;20(7):808-813. doi: https:\/\/doi.org\/10.1007\/s002689900123","DOI":"10.1007\/s002689900123"},{"key":"ref259","doi-asserted-by":"crossref","unstructured":"Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism\u2014a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck\u2019s Arch Surg. 2015;400(8):867-886. doi: https:\/\/doi.org\/10.1007\/s00423-015-1342-7","DOI":"10.1007\/s00423-015-1342-7"},{"key":"ref260","doi-asserted-by":"crossref","unstructured":"Iacobone M, Masi G, Barzon L, et al. Hyperparathyroidism\u2013jaw tumor syndrome: a report of three large kindred. Langenbeck\u2019s Arch Surg. 2009;394(5):817-825. doi: https:\/\/doi.org\/10.1007\/s00423-009-0511-y","DOI":"10.1007\/s00423-009-0511-y"},{"key":"ref261","unstructured":"Jackson CE, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108(6):1006-1012; discussion 1012-1013."},{"key":"ref262","doi-asserted-by":"crossref","unstructured":"van der Tuin K, Tops CMJ, Adank MA, et al. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2017;102(12):4534-4540. doi: https:\/\/doi.org\/10.1210\/jc.2017-01249","DOI":"10.1210\/jc.2017-01249"},{"key":"ref263","doi-asserted-by":"crossref","unstructured":"Pichardo-Lowden AR, Manni A, Saunders BD, Baker MJ. Familial Hyperparathyroidism Due to A Germline Mutation of the Cdc73 Gene: Implications for Management and Age-Appropriate Testing of Relatives At Risk. Endocr Pract. 2011;17(4):602-609. doi: https:\/\/doi.org\/10.4158\/EP10337.RA","DOI":"10.4158\/EP10337.RA"},{"key":"ref264","doi-asserted-by":"crossref","unstructured":"Harman CR. Sporadic Primary Hyperparathyroidism in Young Patients. Arch Surg. 1999;134(6):651-656. doi: https:\/\/doi.org\/10.1001\/archsurg.134.6.651","DOI":"10.1001\/archsurg.134.6.651"},{"key":"ref265","doi-asserted-by":"crossref","unstructured":"Lee M, Pellegata NS. Multiple Endocrine Neoplasia Type 4. Hormone and Metabolic Research. 2013;41:63-78. doi: https:\/\/doi.org\/10.1159\/000345670","DOI":"10.1159\/000345670"},{"key":"ref266","doi-asserted-by":"crossref","unstructured":"Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736-1741. doi: https:\/\/doi.org\/10.1002\/cncr.22599","DOI":"10.1002\/cncr.22599"},{"key":"ref267","doi-asserted-by":"crossref","unstructured":"Talat N, Schulte K-M. Clinical Presentation, Staging and Long-Term Evolution of Parathyroid Cancer. Ann Surg Oncol. 2010;17(8):2156-2174. doi: https:\/\/doi.org\/10.1245\/s10434-010-1003-6","DOI":"10.1245\/s10434-010-1003-6"},{"key":"ref268","doi-asserted-by":"crossref","unstructured":"Ryh\u00e4nen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol (Madr). 2017;56(7):991-1003. doi: https:\/\/doi.org\/10.1080\/0284186X.2017.1306103","DOI":"10.1080\/0284186X.2017.1306103"},{"key":"ref269","doi-asserted-by":"crossref","unstructured":"Mokrysheva NG, Krupinova JA, Mirnaya SS. Clinical, laboratory and instrumental methods of pre-surgical diagnosis of the parathyroid glands cancer. Endocr Surg. 2017;11(3):136-145. (In Russ.) doi: https:\/\/doi.org\/10.14341\/serg20173136-145","DOI":"10.14341\/serg20173136-145"},{"key":"ref270","doi-asserted-by":"crossref","unstructured":"Nam M, Jeong HS, Shin JH. Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. Acta radiol. 2017;58(6):670-675. doi: https:\/\/doi.org\/10.1177\/0284185116666418","DOI":"10.1177\/0284185116666418"},{"key":"ref271","doi-asserted-by":"crossref","unstructured":"Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. Head Neck. 2013;35(1):35-39. doi: https:\/\/doi.org\/10.1002\/hed.22908","DOI":"10.1002\/hed.22908"},{"key":"ref272","doi-asserted-by":"crossref","unstructured":"Shane E. Parathyroid Carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-493. doi: https:\/\/doi.org\/10.1210\/jcem.86.2.7207","DOI":"10.1210\/jcem.86.2.7207"},{"key":"ref273","doi-asserted-by":"crossref","unstructured":"Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: A 22-year experience. Head Neck. 2004;26(8):716-726. doi: https:\/\/doi.org\/10.1002\/hed.20049","DOI":"10.1002\/hed.20049"},{"key":"ref274","doi-asserted-by":"crossref","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer. 1999;86(3):538-544. doi: https:\/\/doi.org\/10.1002\/ (SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-K","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-K"},{"key":"ref275","doi-asserted-by":"crossref","unstructured":"Montenegro FL de M, Tavares MR, Durazzo MD, et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J. 2006;124(1):42-44. doi: https:\/\/doi.org\/10.1590\/S1516-31802006000100009","DOI":"10.1590\/S1516-31802006000100009"},{"key":"ref276","doi-asserted-by":"crossref","unstructured":"Villar-del-Moral J, Jim\u00e9nez-Garc\u00eda A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: A multicenter cohort study. Surgery. 2014;156(5):1132-1144. doi: https:\/\/doi.org\/10.1016\/j.surg.2014.05.014","DOI":"10.1016\/j.surg.2014.05.014"},{"key":"ref277","doi-asserted-by":"crossref","unstructured":"Schulte KM, Talat N, Galata G, et al. Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer. Ann Surg Oncol. 2014;21(6):1891-1897. doi: https:\/\/doi.org\/10.1245\/s10434-014-3530-z","DOI":"10.1245\/s10434-014-3530-z"},{"key":"ref278","doi-asserted-by":"crossref","unstructured":"Mamedova EO, Mokrysheva NG, Pigarova EA, et al. CDC73 mutations in young patients with primary hyperparathyroidism: A description of two clinical cases. Terapevticheskii arkhiv. 2016;88(10):57-62. (In Russ.) doi: https:\/\/doi.org\/10.17116\/terarkh201688657-62","DOI":"10.17116\/terarkh201688657-62"},{"key":"ref279","doi-asserted-by":"crossref","unstructured":"Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog ( CDC73 ) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31(3):295-307. doi: https:\/\/doi.org\/10.1002\/humu.21188","DOI":"10.1002\/humu.21188"},{"key":"ref280","doi-asserted-by":"crossref","unstructured":"Pandya C, Uzilov A V., Bellizzi J, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017;2(6). doi: https:\/\/doi.org\/10.1172\/jci.insight.92061","DOI":"10.1172\/jci.insight.92061"},{"key":"ref281","doi-asserted-by":"crossref","unstructured":"Demir H, Halac M, Gorur GD, et al. FDG PET\/CT findings in primary hyperparathyroidism mimicking multiple bone metastases. Eur J Nucl Med Mol Imaging. 2008;35(3):686-686. doi: https:\/\/doi.org\/10.1007\/s00259-007-0653-5","DOI":"10.1007\/s00259-007-0653-5"},{"key":"ref282","doi-asserted-by":"crossref","unstructured":"Mokrysheva NG, Krupinova YuA, Dolgushin MB, et al. Positron emission tomography in combination with computed tomography with 18F-fluorocholine in the topical diagnosis of parathyroid tumors and secondary changes in bone tissue associated with hyperparathyroid osteodystrophy: two case studies. Problems of Endocrinology. 2018;64(5):299-305. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl9548","DOI":"10.14341\/probl9548"},{"key":"ref283","doi-asserted-by":"crossref","unstructured":"Gahier Penhoat M, Drui D, Ansquer C, et al. Contribution of 18-FDG PET\/CT to brown tumor detection in a patient with primary hyperparathyroidism. Jt Bone Spine. 2017;84(2):209-212. doi: https:\/\/doi.org\/10.1016\/j.jbspin.2016.06.007","DOI":"10.1016\/j.jbspin.2016.06.007"},{"key":"ref284","unstructured":"Calandra D, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery, 1984;96(6):1132-1137."},{"key":"ref285","doi-asserted-by":"crossref","unstructured":"Bukowski RM. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med. 1984;144(2):399-400. doi: https:\/\/doi.org\/10.1001\/archinte.144.2.399","DOI":"10.1001\/archinte.144.2.399"},{"key":"ref286","doi-asserted-by":"crossref","unstructured":"Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: Is there a role for adjuvant radiation therapy? Cancer. 2003;98(11):2378-2384. doi: https:\/\/doi.org\/10.1002\/cncr.11819","DOI":"10.1002\/cncr.11819"},{"key":"ref287","doi-asserted-by":"crossref","unstructured":"Wynne AG, Heerden J Van, Carney JA, Fitzpatrick LA. Parathyroid Carcinoma. Medicine (Baltimore). 1992;71(4):197-205. doi: https:\/\/doi.org\/10.1097\/00005792-199207000-00002","DOI":"10.1097\/00005792-199207000-00002"},{"key":"ref288","doi-asserted-by":"crossref","unstructured":"Tong CV, Hussein Z, Noor NM, et al. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM. 2015;108(1):49-50. doi: https:\/\/doi.org\/10.1093\/qjmed\/hcu166","DOI":"10.1093\/qjmed\/hcu166"},{"key":"ref289","unstructured":"Sanden A.K., Vestergaard P. Kontrol af serumcalcium med cinacalcet ved parathyroideacancer. Ugeskrift for Laeger. 2009;171(41):3004-3006."},{"key":"ref290","doi-asserted-by":"crossref","unstructured":"\u00c7alapkulu M, Gul OO, Cander S, et al. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma. J Coll Physicians Surg Pakistan. 2020;30(7):757-759. doi: https:\/\/doi.org\/10.29271\/jcpsp.2020.07.757","DOI":"10.29271\/jcpsp.2020.07.757"},{"key":"ref291","doi-asserted-by":"crossref","unstructured":"Fountas A, Tigas S, Tsatsoulis A. Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. QJM. 2017;110(1):53-54. doi: https:\/\/doi.org\/10.1093\/qjmed\/hcw206","DOI":"10.1093\/qjmed\/hcw206"},{"key":"ref292","doi-asserted-by":"crossref","unstructured":"Takeuchi Y, Takahashi S, Miura D, et al. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab. 2017;35(6):616-622. doi: https:\/\/doi.org\/10.1007\/s00774-016-0797-0","DOI":"10.1007\/s00774-016-0797-0"},{"key":"ref293","doi-asserted-by":"crossref","unstructured":"Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma. J Clin Endocrinol Metab. 2007;92(10):3803-3808. doi: https:\/\/doi.org\/10.1210\/jc.2007-0585","DOI":"10.1210\/jc.2007-0585"},{"key":"ref294","doi-asserted-by":"crossref","unstructured":"Rozhinskaya L, Pigarova E, Sabanova E, et al. Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Reports. 2017;2017. doi: https:\/\/doi.org\/10.1530\/EDM-16-0113","DOI":"10.1530\/EDM-16-0113"},{"key":"ref295","doi-asserted-by":"crossref","unstructured":"Alharbi N, Asa SL, Szybowska M, et al. Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Front Endocrinol (Lausanne). 2018;9:641. doi: https:\/\/doi.org\/10.3389\/fendo.2018.00641","DOI":"10.3389\/fendo.2018.00641"},{"key":"ref296","doi-asserted-by":"crossref","unstructured":"Mokrysheva MNG, Lipatenkova LAK, Taller TNA. Primary hyperparathyroidism and pregnancy. Obstetrics and Gynecology. 2016;10:18-25. (In Russ.) doi: https:\/\/doi.org\/10.18565\/aig.2016.10.18-25","DOI":"10.18565\/aig.2016.10.18-25"},{"key":"ref297","doi-asserted-by":"crossref","unstructured":"Norman J, Politz D, Politz L. Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: a call for earlier intervention. Clin Endocrinol (Oxf ). 2009;71(1):104-109. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03495.x","DOI":"10.1111\/j.1365-2265.2008.03495.x"},{"key":"ref298","doi-asserted-by":"crossref","unstructured":"Schnatz PF, Curry SL. Primary Hyperparathyroidism in Pregnancy:Evidence-Based Management. Obstet Gynecol Surv. 2002;57(6):365-376. doi: https:\/\/doi.org\/10.1097\/00006254-200206000-00022","DOI":"10.1097\/00006254-200206000-00022"},{"key":"ref299","doi-asserted-by":"crossref","unstructured":"Hirsch D, Kopel V, Nadler V, et al. Pregnancy Outcomes in Women With Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(5):2115-2122. doi: https:\/\/doi.org\/10.1210\/jc.2015-1110","DOI":"10.1210\/jc.2015-1110"},{"key":"ref300","doi-asserted-by":"crossref","unstructured":"Cassir G, Sermer C, Malinowski AK. Impact of Perinatal Primary Hyperparathyroidism on Maternal and Fetal and Neonatal Outcomes: Retrospective Case Series. J Obstet Gynaecol Canada. 2020;42(6):750-756. doi: https:\/\/doi.org\/10.1016\/j.jogc.2019.12.017","DOI":"10.1016\/j.jogc.2019.12.017"},{"key":"ref301","doi-asserted-by":"crossref","unstructured":"McMullen TPW, Learoyd DL, Williams DC, et al. Hyperparathyroidism in Pregnancy: Options for Localization and Surgical Therapy. World J Surg. 2010;34(8):1811-1816. doi: https:\/\/doi.org\/10.1007\/s00268-010-0569-2","DOI":"10.1007\/s00268-010-0569-2"},{"key":"ref302","doi-asserted-by":"crossref","unstructured":"Vitetta GM, Neri P, Chiecchio A, et al. Role of ultrasonography in the management of patients with primary hyperparathyroidism: retrospective comparison with technetium-99m sestamibi scintigraphy. J Ultrasound. 2014;17(1):1-12. doi: https:\/\/doi.org\/10.1007\/s40477-014-0067-8","DOI":"10.1007\/s40477-014-0067-8"},{"key":"ref303","unstructured":"Kelly TR. Primary hyperparathyroidism during pregnancy. Surgery. 1991;110(6):1028-1034."},{"key":"ref304","unstructured":"Kristoffersson A, et al. Primary hyperparathyroidism in pregnancy. Surgery. 1985;97(3):326-330."},{"key":"ref305","unstructured":"Walker A, Fraile JJ, Hubbard JG. \u201cParathyroidectomy in pregnancy\u201d-a single centre experience with review of evidence and proposal for treatment algorithim. Gland Surg. 2014;3(3):148. doi: https:\/\/doi.org\/10.3978\/j.issn.2227-684X.2014.02.04"},{"key":"ref306","doi-asserted-by":"crossref","unstructured":"Hu Y, Cui M, Sun Z, et al. Clinical Presentation, Management, and Outcomes of Primary Hyperparathyroidism during Pregnancy. Int J Endocrinol. 2017;2017:1-7. doi: https:\/\/doi.org\/10.1155\/2017\/3947423","DOI":"10.1155\/2017\/3947423"},{"key":"ref307","doi-asserted-by":"crossref","unstructured":"McCarthy A, Howarth S, Khoo S, et al. Management of primary hyperparathyroidism in pregnancy: a case series. Endocrinol Diabetes Metab Case Reports. 2019;2019. doi: https:\/\/doi.org\/10.1530\/EDM-19-0039","DOI":"10.1530\/EDM-19-0039"},{"key":"ref308","doi-asserted-by":"crossref","unstructured":"Trebb C, Wallace S, Ishak F, Splinter KL. Concurrent Parathyroidectomy and Caesarean Section in the Third Trimester. J Obstet Gynaecol Canada. 2014;36(6):502-505. doi: https:\/\/doi.org\/10.1016\/S1701-2163(15)30564-8","DOI":"10.1016\/S1701-2163(15)30564-8"},{"key":"ref309","doi-asserted-by":"crossref","unstructured":"Krysiak R, Wilk M, Okopien B. Recurrent pancreatitis induced by hyperparathyroidism in pregnancy. Arch Gynecol Obstet. 2011;284(3):531-534. doi: https:\/\/doi.org\/10.1007\/s00404-010-1668-x","DOI":"10.1007\/s00404-010-1668-x"},{"key":"ref310","doi-asserted-by":"crossref","unstructured":"Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428-430. doi: https:\/\/doi.org\/10.1016\/j.bone.2008.11.001","DOI":"10.1016\/j.bone.2008.11.001"},{"key":"ref311","doi-asserted-by":"crossref","unstructured":"Vera L, Oddo S, Di Iorgi N, et al. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. J Med Case Rep. 2016;10(1):361. doi: https:\/\/doi.org\/10.1186\/s13256-016-1093-2","DOI":"10.1186\/s13256-016-1093-2"},{"key":"ref312","doi-asserted-by":"crossref","unstructured":"Horjus C, Groot I, Telting D, et al. Cinacalcet for Hyperparathyroidism in Pregnancy and Puerperium. J Pediatr Endocrinol Metab. 2009;22(8):741-750. doi: https:\/\/doi.org\/10.1515\/JPEM.2009.22.8.741","DOI":"10.1515\/JPEM.2009.22.8.741"},{"key":"ref313","doi-asserted-by":"crossref","unstructured":"Nadarasa K, Bailey M, Chahal H, et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Reports. 2014;2014. doi: https:\/\/doi.org\/10.1530\/EDM-14-0056","DOI":"10.1530\/EDM-14-0056"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/12801\/9964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T14:06:13Z","timestamp":1673273173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/12801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":313,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,9,16]]}},"URL":"https:\/\/doi.org\/10.14341\/probl12801","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}